Novo Nordisk's best-selling diabetes treatment drug Ozempic is back on the shelves in the United States after months of shortage, the U.S. Food and Drug Administration (FDA) website showed on Friday.
best-selling diabetes treatment drug Ozempic is back on the shelves in the United States after months of shortage, the U.S. Food and Drug Administration website showed on Friday.
The main active ingredient in Ozempic is semaglutide, also the key ingredient in Novo's obesity drug Wegovy, which has been seeing supply shortage due to high demand. The company said the 0.25 mg, 0.5 mg and the 1 mg doses of Ozempic are available for patients. The 2 mg dose, however, has limited availability until the end of this month, largely due to the demand coupled with overall global supply constraints.
"While product continues to be manufactured and shipped, patients in some areas of the country will experience delays with the 2mg dose," Novo Nordisk said.of supply constraints this year on Ozempic. The drug recorded sales of 59.75 billion Danish crowns in 2022. Ozempic's demand was also seen to be partly driven by prescriptions to non-diabetic patients seeking to lose weight, which is outside the drug's approved indication.Our Standards:
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk suspended from UK lobby groupDanish drugmaker Novo Nordisk has been suspended from the Association of the British Pharmaceutical Industry (ABPI) for two years over what the ABPI on Thursday described as 'serious breaches' of its code of practice.
Read more »
Sanofi to slash U.S. insulin prices in 2024 after similar cuts by Eli Lilly and Novo NordiskThe French drugmaker is the last major insulin manufacturer to try to head off government efforts to cap monthly costs by announcing its own steep price cuts.
Read more »
Sanofi is the latest insulin maker to announce price capSanofi joins Eli Lilly and Novo Nordisk to cap insulin prices. President Joe Biden still wants Congress to enact limits. MORE ⬇️
Read more »
Sanofi to Cut US Price of Its Most-Prescribed Insulin by 78%Sanofi said on Thursday it will cut US list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by rivals Novo Nordisk and Eli Lilly.
Read more »
TikTok's Fave Weight Loss Drugs: Link to Thyroid Cancer?Demand for Ozempic continues to surge, fueled by social media; but research suggests that for some, use of these injectables may be linked to increased risk for thyroid cancer.
Read more »